![Molecular Therapy Family's Impact Factor Increased 44 Percent in 2020 | ASGCT - American Society of Gene & Cell Therapy Molecular Therapy Family's Impact Factor Increased 44 Percent in 2020 | ASGCT - American Society of Gene & Cell Therapy](https://asgct.org/ASGCT/media/about/MT-IF-banner.png)
Molecular Therapy Family's Impact Factor Increased 44 Percent in 2020 | ASGCT - American Society of Gene & Cell Therapy
![Mohamed Abou-el-Enein on Twitter: "We are thankful to the scientific community and our reviewers for contributing to this wonderful achievement. The impact factor of Molecular Therapy - Methods and Clinical Development increased Mohamed Abou-el-Enein on Twitter: "We are thankful to the scientific community and our reviewers for contributing to this wonderful achievement. The impact factor of Molecular Therapy - Methods and Clinical Development increased](https://pbs.twimg.com/media/E5ZkzEqVkAAZyyD.jpg)
Mohamed Abou-el-Enein on Twitter: "We are thankful to the scientific community and our reviewers for contributing to this wonderful achievement. The impact factor of Molecular Therapy - Methods and Clinical Development increased
Molecular Therapy-Methods & Clinical Development影响因子,是几区,期刊投稿经验分享,Molecular Therapy-Methods & Clinical Development 主页,推荐审稿人、编辑,审稿周期/时间,版面费多少,中国作者发表文章,修改意见
![Molecular Therapy - Methods & Clinical Development | Vol 11, Pages 1-202 (14 December 2018) | ScienceDirect.com by Elsevier Molecular Therapy - Methods & Clinical Development | Vol 11, Pages 1-202 (14 December 2018) | ScienceDirect.com by Elsevier](https://ars.els-cdn.com/content/image/1-s2.0-S2329050118X00035-cov200h.gif)
Molecular Therapy - Methods & Clinical Development | Vol 11, Pages 1-202 (14 December 2018) | ScienceDirect.com by Elsevier
![Molecular Therapy - Methods & Clinical Development | Vol 6, Pages 1-230 (15 September 2017) | ScienceDirect.com by Elsevier Molecular Therapy - Methods & Clinical Development | Vol 6, Pages 1-230 (15 September 2017) | ScienceDirect.com by Elsevier](https://ars.els-cdn.com/content/image/1-s2.0-S2329050117X00041-cov200h.gif)
Molecular Therapy - Methods & Clinical Development | Vol 6, Pages 1-230 (15 September 2017) | ScienceDirect.com by Elsevier
![Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief | ASGCT - American Society of Gene & Cell Therapy Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief | ASGCT - American Society of Gene & Cell Therapy](https://asgct.org/ASGCT/media/about/Herzog-Bauer-on-page.png)
Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief | ASGCT - American Society of Gene & Cell Therapy
Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec
![Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on CyberLeninka Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on CyberLeninka](https://cyberleninka.org/viewer_images/1500232/f/1.png)
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on CyberLeninka
![PDF) Gene Therapy for Parkinson's Disease: preclinical evaluation of an optimally configured TH:CH1 fusion for maximal Dopamine synthesis PDF) Gene Therapy for Parkinson's Disease: preclinical evaluation of an optimally configured TH:CH1 fusion for maximal Dopamine synthesis](https://i1.rgstatic.net/publication/334518897_Gene_Therapy_for_Parkinson's_Disease_preclinical_evaluation_of_an_optimally_configured_THCH1_fusion_for_maximal_Dopamine_synthesis/links/5d54392c92851c93b6303946/largepreview.png)